companies making glp 1 drugs GLP-1 2.0: Where the Next Wave of Value Will Be Created companies that make glp 1

Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity

GLP-1 drugs such as semaglutide are reshaping treatment of obesity, diabetes and cardiovascular disease with broader physiological effects now emerging.

A balanced microbiome environment can help support pathways involved in energy metabolism and appetite regulation

While some ingredients show limited potential, the evidence remains nuanced and should be interpreted carefully

The data are provided by patients and collected by the UK National Health Service as part of their care and support